Bicycle Therapeutics (BCYC) Q3 2026 earnings review
Bicycle Therapeutics cuts its cash burn, but key trials slip
Bicycle Therapeutics, a drug developer using synthetic peptides to treat cancer, cut its operating costs while pulling back on its furthest-along medicine. Operating expenses dropped 39% after two rounds of layoffs and a decision to scale back its bladder cancer program, extending the company's cash life into 2030. Collaboration revenue nearly tripled to $34 million, but that jump came from an accounting boost after Bayer ended its partnership with the firm.
| Operating expenses | $47.5M -38.5% from a year ago |
|---|---|
| Collaboration revenue | $34.1M +190.2% from a year ago |
| Cash and cash equivalents | $469.9M $628.1M at the end of 2025 |
| Cash runway outlook | Extended into 2030, up from 2028 |
⚖️ Verdict: 🔴 Bearish
The story got worse because clinical delays and lost partnerships outweigh the longer cash life. Chief executive Kevin Lee is now relying on an earlier-stage pancreatic cancer drug and a radiation therapy that will not enter human testing until late 2027, a year behind the prior schedule. The good news: shrinking the workforce and pausing late-stage trials preserves the $470 million cash pile for four more years.
The question now is whether the pancreatic cancer drug can replace the deprioritized bladder cancer program as a viable commercial medicine. If the Phase 2 trial shows strong tumor responses, the smaller pipeline still holds value; if it falls short, the company waits until late 2027 just to begin human testing on its radiation platform. Clinical data in 2027 will decide it.
🐂 Bull Case
Cost Cuts Extend Cash Life Into 2030
Bicycle Therapeutics, a drug developer using synthetic peptides to target cancer, cut its operating spending by 38.5% from a year ago to $47.5 million. The UK-based group achieved these savings after two rounds of "workforce reductions announced in August 2025 and March 2026" and lower clinical trial spending.
- Research and development costs: $33.4 million, down 42.8% from a year ago
- General and administrative overhead: $14.1 million, down 25.2% from a year ago
- Cash and cash equivalents: $469.9 million, down from $628.1 million at the end of 2025
In percentage points of revenue, research spending fell 399.8 points and overhead fell 119.3 points. Because the drugmaker lowered its quarterly cash burn, it now expects its $469.9 million cash pile to fund operations into 2030, two years longer than its 2025 plan.
What to watch: fourth-quarter operating expenses in the full-year report. That figure will show where quarterly cash burn settles now that the two staff reductions are complete.
FDA Grants Special Status to Pancreatic Cancer Drug
"We believe the FDA’s Orphan Drug Designation for nuzefatide in pancreatic cancer further supports our development strategy and underscores the significant unmet need in this patient population," chief executive Kevin Lee said. Nuzefatide pevedotin is an experimental therapy that attaches a cancer-killing payload to a peptide targeting EphA2, a protein found on tumors.
US regulators granted this status in September 2026 for pancreatic cancer, which gives the biotech company tax credits on clinical trial costs, fee waivers, and seven years of market exclusivity if the medicine wins approval. The firm is currently enrolling patients with recurrent pancreatic cancer in a mid-stage Phase 2 trial.
What to watch: clinical trial updates from the Phase 2 pancreatic cancer study in 2027. Strong tumor response rates would validate nuzefatide pevedotin as the company's new lead internal medicine.
🐻 Bear Case
Revenue Jump Comes From a Canceled Partnership
Bicycle reported $34.1 million in third-quarter collaboration revenue, nearly triple the $11.7 million it recorded a year ago. That accounting jump shrunk the quarterly net loss from $59.1 million to $10.5 million, or $0.15 per share.
However, the revenue increase did not come from a new scientific milestone. The company said the jump resulted from the "recognition of all remaining revenue under Bicycle Therapeutics’ collaboration with Bayer Consumer Care AG" following the "termination of the underlying collaboration agreement". By our math, the drugmaker booked only $1.5 million of revenue across the entire first half of 2026. Losing Bayer eliminates a pharmaceutical partner and leaves no remaining deferred revenue from that contract.
What to watch: fourth-quarter collaboration revenue in the annual report. Without the one-off accounting boost from the ended Bayer deal, revenue will drop back toward first-half levels.
Bladder Cancer Drug Deprioritized After Trial Downsizing
Zelenectide pevedotin is a targeted cancer therapy built to bind to Nectin-4, a protein common in bladder and breast tumors. In 2025, this medicine was the biotech group's primary clinical focus and largest driver of research spending.
The company disclosed that it "converted the Duravelo-2 trial to a randomized Phase 2 trial in May 2026 and deprioritized the program for internal development". Pulling back on its most advanced clinical asset explains why research spending fell by $25.0 million this quarter, but it leaves the pipeline relying on earlier-stage candidates.
What to watch: survival data from the downsized Duravelo-2 bladder cancer trial in the second half of 2027. Positive survival numbers could help Lee attract an external partner to fund late-stage development.
First Radioligand Human Trial Pushed to Late 2027
Bicycle is building a pipeline of radioconjugates, which use peptides to deliver radioactive isotopes directly to tumors. Throughout 2025, management told investors it planned to start its first company-sponsored human trial for this radiation platform in 2026.
The drugmaker now expects the "Initiation of the first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP- targeting Bicycle ® Radioconjugate, expected in 2H 2027". While the delay preserves cash right now, it pushes clinical validation of the radiation delivery platform back by more than a year.
What to watch: patient dosing in the BT1702 trial in the second half of 2027. Starting the study on time will show whether the radiation program has overcome its development delays.
💲 Other KPIs
Working capital — short-term assets minus short-term liabilities — fell 26.4% from a year ago and dropped from $625.9 million at the end of 2025. The balance shrank because the biotech group spent cash to fund its clinical trials, though lower operating expenses slowed the pace of decline this quarter.
Weighted average ordinary shares rose 1.0% from a year ago, up from 69.3 million in the third quarter of 2025. With $469.9 million in cash on the balance sheet, the UK company did not need to issue new equity to fund its operations over the past year.
Interest earned on cash deposits dropped 37.1% from $6.7 million a year ago. For the first nine months of 2026, interest income totaled $13.5 million versus $22.6 million in the prior-year period, declining alongside the smaller cash balance.
🔮 Guidance
Raised. Bicycle now expects its $469.9 million in cash to fund operations into 2030, extending the 2028 timeline it set in 2025. Two rounds of layoffs in August 2025 and March 2026, along with scaling back the zelenectide bladder cancer program, lowered quarterly operating burn enough to add two years of funding.
Cut. The company now plans to start its first human trial for BT1702, a radiation-carrying peptide targeting MT1-MMP, in the second half of 2027. Across all four quarters of 2025, management had targeted starting its first company-sponsored radioligand trial in 2026.
Cut. After converting the Duravelo-2 bladder cancer study into a smaller Phase 2 trial and deprioritizing the drug in May 2026, the firm plans to report survival data in late 2027. Management had previously pointed to an update on dose selection and the approval pathway in early 2026.
Cut. The drugmaker expects to share clinical updates from its Phase 2 trial of nuzefatide pevedotin in recurrent pancreatic cancer in 2027. In late 2025, the plan called for presenting Phase 1 combination data for the same molecule in the first half of 2026.
❓ Key Questions
Why did Bayer end its partnership with Bicycle?
Recognizing all remaining revenue from the terminated Bayer deal added $34.1 million this quarter, but management did not explain why Bayer walked away or whether other partner programs face similar risks.
Will Bicycle seek a partner for zelenectide pevedotin?
The company deprioritized zelenectide for internal development but continues running the Phase 2 bladder cancer trial until late 2027. Investors need to know if the goal is to license the drug out.
What pushed the BT1702 radiation trial to late 2027?
Management previously planned to start its first radioligand clinical trial in 2026. The release gives no reason for the delay to the second half of 2027.
What Happened to the breast and lung cancer trials?
In 2025, the company opened the Duravelo-3 breast cancer and Duravelo-4 lung cancer trials for zelenectide. Neither study appears in this quarter's release.